Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 574

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 574
---
817 | ) |
| Represents estimated transaction costs to be incurred by Denali and Semnur subsequent to the balance sheet date                       |     |   |  (5,569 | ) |
| Reflects share repayment of Promissory Notes issued as of balance sheet date                                                          |     |   |   3,078 |   |
| Reflects share repayment of Promissory Notes issued subsequent to the balance sheet date                                              |     |   |      96 |   |
| Represents additional paid-in capital for deferred underwriting fees as of balance sheet date to be settled in shares (see (G) above) |     |   |     866 |   |
| Reclassification of Denali redeemable common stock                                                                                    |     |   |     527 |   |
| Reflects recapitalization of Semnur(1)                                                                                                |     |   |  59,981 |   |
| Total                                                                                                                                 |     | $ |  41,425 |   |

354

| (1) | The adjustment to additional paid-in capital for recapitalization of Semnur is derived as follows: |

| (In thousands)                                                                                             |     |   |        |   |
|:-----------------------------------------------------------------------------------------------------------|:----|:--|-------:|:--|
| Additional funding to be provided by Scilex to Semnur subsequent to the balance sheet date (see (A) above) |     | $ |  9,245 |   |
| Plus: Elimination of Related Party Loan as of balance sheet date (see (F) above)                           |     |   | 50,755 |   |
| Plus: Elimination of historical par value Semnur Common Stock (see (I) above)                              |     |   |      2 |   |
| Less: Par value of New Semnur Common Stock issued to Scilex                                                |     |   |    (20 | ) |
| Less: Par value of New Semnur Preferred Stock issued to Scilex                                             |     |   |     (1 | ) |
| Increase in additional paid-in capital due to recapitalization of Semnur                                   |     | $ | 59,981 |   |

| (K) | Reflects pro forma adjustments to accumulated deficit as follows: |

| (In thousands)                                                                                                                                                              |     |   |        |   |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--|-------:|:--|
| Represents estimated